ImmuCell Co. (NASDAQ:ICCC – Get Free Report) was the recipient of a significant decrease in short interest in June. As of June 30th, there was short interest totalling 5,700 shares, a decrease of 12.3% from the June 15th total of 6,500 shares. Based on an average daily trading volume, of 11,700 shares, the short-interest ratio is currently 0.5 days. Currently, 0.1% of the shares of the stock are short sold.
ImmuCell Price Performance
ImmuCell stock traded up $0.02 during trading hours on Wednesday, reaching $4.29. 4,853 shares of the stock were exchanged, compared to its average volume of 9,330. The company has a market cap of $33.50 million, a P/E ratio of -8.22 and a beta of 0.58. The company has a current ratio of 2.71, a quick ratio of 1.00 and a debt-to-equity ratio of 0.41. ImmuCell has a twelve month low of $4.05 and a twelve month high of $5.87. The stock has a 50 day moving average of $4.51 and a two-hundred day moving average of $4.92.
ImmuCell (NASDAQ:ICCC – Get Free Report) last announced its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter. ImmuCell had a negative return on equity of 15.21% and a negative net margin of 18.31%. The firm had revenue of $7.26 million for the quarter.
Institutional Investors Weigh In On ImmuCell
ImmuCell Company Profile
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.
Featured Stories
- Five stocks we like better than ImmuCell
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Real Estate Stock Signals a Boom in Manufacturing Activity
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- This Medical Giant’s Stock Rebounds: A 15% Upside Is the Minimum
- How to invest in marijuana stocks in 7 stepsĀ
- Financial Giant’s Shares Soar on EPS Beat and Record Asset Levels
Receive News & Ratings for ImmuCell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuCell and related companies with MarketBeat.com's FREE daily email newsletter.